GENERAL SUMMARY OF POSITION:
The Donahue lab is working to define mechanisms of abnormal heart rhythms, and from that information, to develop novel therapies for atrial fibrillation (AF) and ventricular tachycardia (VT). As a means to that end, the lab has developed several gene therapy methods and created novel pig models of AF and VT. We were first to show efficacy of gene therapy for a cardiac arrhythmia in a 12/2000 Nature Medicine publication. That work was cited as one of the top 10 advances in cardiac research for the year by the American Heart Association. We have also shown preclinical efficacy for elimination of atrial fibrillation and post-myocardial infarction ventricular arrhythmias in our pig models, using a variety of treatment strategies with gene therapy. Our ongoing interests include the investigation of mechanisms for post-infarct VT and chronic AF, the development of improved gene delivery methods, and the use of these methods for arrhythmia gene therapy.
Prior experience with sterile technique, surgical procedures, preferably in large mammals and animal care.
Under the direction of the Principal Investigator, or designee
May functionally supervise aides, technicians, and associates
ENVIRONMENTAL WORKING CONDITIONS:
Wet chemistry laboratory, and may require appropriate contact with biohazards, radionuclides, toxins, animals, and human specimens.